发明名称 |
Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one |
摘要 |
The invention relates to crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one, processes for the preparation thereof, pharmaceutical compositions containing said crystalline forms, and their use as compounds improving vascular function and as immunomodulating agents, either alone or in combination with other active compounds or therapies. |
申请公布号 |
US9062014(B2) |
申请公布日期 |
2015.06.23 |
申请号 |
US200913125102 |
申请日期 |
2009.10.19 |
申请人 |
ACTELION PHARMACEUTICALS LTD. |
发明人 |
Bonham Nicholas;Buchmann Stephan;Eberlin Alex;Imboden Christoph;Von Raumer Markus |
分类号 |
A61K31/426;C07D277/54 |
主分类号 |
A61K31/426 |
代理机构 |
Hoxie & Associates LLC |
代理人 |
Hoxie & Associates LLC |
主权项 |
1. A crystalline form of the compound (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one containing from 0 to 0.5 equivalents of H2O per equivalent of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one, characterised by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 7.0°, 11.2°, and 12.6°, wherein the X-ray powder diffraction diagram is obtained by using Cu Kα1 radiation (λ=1.5406 Å), and wherein the accuracy of the 2θ values is in the range of +/− 0.2°. |
地址 |
Allschwil CH |